Skip to content
OpenCapital
Get started

AbCellera Biologics Inc. ABCL Cash Provided by (Used in) Investing Activity, Including Discontinued Operation

Cash Provided by (Used in) Investing Activity, Including Discontinued Operation at other companies

Zymeworks logo
ZymeworksZYME
$69.96M+474%
ADMA Biologics logo
ADMA BiologicsADMA
$2.4M+151%
ALN
Alnylam PharmaceuticalsALNY
-$25.54M-122%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
-$268.65M-1,092%
Roivant Sciences logo
Roivant SciencesROIV
——
Revvity logo
RevvityRVTY
——

Other financials

Income statement

See full
Revenue$8.3M+96.3%
Operating income-$57.5M+8.2%
Net income-$43.2M+5.4%
EPS (diluted)-$0.14+6.7%

Balance sheet

See full
Cash & equivalents$102.1M-44.6%
Total debt$140.2M+107%
Total equity$938.1M-8.3%
Total assets$1.3B-2.8%

Cash flow

See full
Operating cash flow-$33.5M-190%
CapEx$3.8M-64.0%
Free cash flow-$37.4M-68.3%

Valuation

See full
Market cap$1.84B+59.2%

Profitability

See full
Operating margin-267.6%-120pp
Net margin-181.7%-77.9pp
FCF margin-238.9%-90.9pp

Returns & leverage

See full
Return on equity-14.7%-0.8pp
Debt / equity0.1×+0.1×
Current ratio14.1×+3.9×

Where this comes from

Reported directly by AbCellera Biologics Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about AbCellera Biologics Inc.'s cash provided by (used in) investing activity, including discontinued operation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AbCellera Biologics Inc.'s cash provided by (used in) investing activity, including discontinued operation?
AbCellera Biologics Inc. (ABCL) reported cash provided by (used in) investing activity, including discontinued operation of -$25.08M in Q1 2026.
How has AbCellera Biologics Inc.'s cash provided by (used in) investing activity, including discontinued operation changed year-over-year?
AbCellera Biologics Inc.'s cash provided by (used in) investing activity, including discontinued operation decreased by 416.1% year-over-year, from $7.94M to -$25.08M.
What is the long-term trend for AbCellera Biologics Inc.'s cash provided by (used in) investing activity, including discontinued operation?
Over 4 years (2021 to 2025), AbCellera Biologics Inc.'s cash provided by (used in) investing activity, including discontinued operation has grown at a -28.3% compound annual growth rate (CAGR), from -$332.25M to $87.75M.
What does cash provided by (used in) investing activity, including discontinued operation mean?
The total net cash flow resulting from all investing activities, including capital expenditures, acquisitions, and the purchase or sale of securities. It serves as a primary indicator of how much capital the company is reinvesting into its long-term growth and asset base.